Deals· August 8, 2026 · 15 min read
Servier's $2.5B Day One deal: tovorafenib (Ojemda) & first EU JCA completion
By Ran Chen#Servier#Day One#Tovorafenib
Topic
Pediatric Glioma
Pediatric low-grade glioma (pLGG) BRAF alterations, RAF inhibitor mechanisms, pediatric neuro-oncology access, and EU HTA assessments.